News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Sergio Cifuentes highlights key limitations of the PLATFORM study on esophagogastric adenocarcinoma
Sergio Cifuentes/X
May 4, 2025, 11:45

Sergio Cifuentes highlights key limitations of the PLATFORM study on esophagogastric adenocarcinoma

Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, posted on X:

“Critiques on the PLATFORM study design
(Cape-Ram maintenance after 1L chemo in advanced esophagogastric adenocarcinoma)
1. Phase II, low power
Only 47 patients randomized. Limited statistical power undermines OS analysis and toxicity data robustness. Exploratory, not practice-changing.
2. Early arm closure
Sponsor withdrawal led to premature termination of the cape-ram arm, introducing potential selection bias and affecting study validity.
3. Suboptimal control: surveillance
Control arm was observation, not active treatment. This may inflate cape-ram efficacy vs. an inactive comparator. Not reflective of clinical practice.
Sergio Cifuentes
4. Obsolete vs. current standard
By design time, CM649 had already shown benefit of chemo+IO followed by IO maintenance. PLATFORM excluded IO entirely—limits its relevance today.
5. Notable toxicity
Grade ≥3 AEs occurred in 57% of cape-ram vs. 32% surveillance. The toxicity burden is significant, especially for patients with controlled disease post-induction.
Sergio Cifuentes
6. Lack of post-progression standard
Despite early closure, most patients did not receive standard second-line chemo-IO. This questions OS benefit attribution solely to cape-ram.”

Sergio Cifuentes

Title: Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM Study

Journal: JCO Oncology Advances

Authors: Anderley Gordon, David Cunningham, Zayn Rajan, Caroline Fong, Clare Peckitt, Laura Satchwell, Susan Cromarty, Ian Chau

Read full article.

More posts featuring Sergio Cifuentes on OncoDaily.

Alexander Bradshaw Anderley Gordon Becky Leamon cancer Caroline Fong Carys Morgan Charlotte Fribbens Clare Peckitt David Cunningham esophagogastric adenocarcinoma Ian Chau Joyce Thompson Katarzyna Piadel Laura Satchwell Michael Davidson Naureen Starling Nicholas Maisey Oleg Zhitkov OncoDaily Oncology PLATFORM study Russell Petty Sergio Cifuentes Shannon Kidd Sheela Rao Susan Cromarty Suzanne Darby Tom Waddell Zayn Rajan
Special Coverage
Insight
May 4, 2025, 11:45
Sergio Cifuentes highlights key limitations of the PLATFORM study on esophagogastric adenocarcinoma
Opinion
May 4, 2025, 11:29
STELLAR II trial at ESTRO 2025: Immunotherapy Combined with Radiotherapy and Chemotherapy Reduces the Need for Surgery in Locally Advanced Rectal Cancer
Blog
May 4, 2025, 11:26
Collaboration between National Societies and Patients can Strengthen Advocacy - ESTRO
Blog
May 4, 2025, 11:14
Marie-Catherine Vozenin Honored with Claudius Regaud Award at ESTRO 2025
Blog
May 4, 2025, 11:13
Princess Dina Mired: A true trailblazer in Pediatric Oncology by Carlos Rodriguez-Galindo
Blog
May 4, 2025, 11:11
Ina Jürgenliemk-Schulz Receives Iridium 192 Award at ESTRO 2025
Societies
May 4, 2025, 11:03
ASCO Urges Lawmakers to Protect Federal Funding for Cancer Research and Prevention
Blog
May 4, 2025, 10:59
Sarah Barrett: A great and busy start to ESTRO25
Blog
May 4, 2025, 10:57
Joanna Metzner-Sadurski: Proud of Ruiling Yuan for Moderating 2025 COP Webinar on Oncology Advocacy
Blog
May 4, 2025, 10:46
Theresa O Donovan: RTTs Experiences and Perceptions of Providing Support to Patients with Acute Psychosocial Distress
Blog
May 4, 2025, 10:39
Andrew Loblaw: 20 year Data Propensity-based analysis of LDR vs HDR boost
Blog
May 4, 2025, 10:29
Enar Recalde: Radiotherapy for Merkel cell carcinoma at ESTRO2025